These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11387054)

  • 1. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology.
    Belldegrun A; Tso CL; Zisman A; Naitoh J; Said J; Pantuck AJ; Hinkel A; deKernion J; Figlin R
    Hum Gene Ther; 2001 May; 12(8):883-92. PubMed ID: 11387054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
    Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
    J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
    Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
    Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.
    Trudel S; Trachtenberg J; Toi A; Sweet J; Li ZH; Jewett M; Tshilias J; Zhuang LH; Hitt M; Wan Y; Gauldie J; Graham FL; Dancey J; Stewart AK
    Cancer Gene Ther; 2003 Oct; 10(10):755-63. PubMed ID: 14502228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
    Pantuck AJ; van Ophoven A; Gitlitz BJ; Tso CL; Acres B; Squiban P; Ross ME; Belldegrun AS; Figlin RA
    J Immunother; 2004; 27(3):240-53. PubMed ID: 15076142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.
    Miles BJ; Shalev M; Aguilar-Cordova E; Timme TL; Lee HM; Yang G; Adler HL; Kernen K; Pramudji CK; Satoh T; Gdor Y; Ren C; Ayala G; Wheeler TM; Butler EB; Kadmon D; Thompson TC
    Hum Gene Ther; 2001 Nov; 12(16):1955-67. PubMed ID: 11686937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human gene therapy for melanoma: CT-guided interstitial injection.
    Waddill W; Wright W; Unger E; Stopeck A; Akporiaye E; Harris D; Grogan T; Schluter S; Hersh E; Stahl S
    AJR Am J Roentgenol; 1997 Jul; 169(1):63-7. PubMed ID: 9207502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck.
    Gleich LL; Gluckman JL; Nemunaitis J; Suen JY; Hanna E; Wolf GT; Coltrera MD; Villaret DB; Wagman L; Castro D; Gapany M; Carroll W; Gillespie D; Selk LM
    Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):775-9. PubMed ID: 11448348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
    Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
    Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leuvectin Vical Inc.
    Kaushik A
    Curr Opin Investig Drugs; 2001 Jul; 2(7):976-81. PubMed ID: 11757801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial.
    Gleich LL; Gluckman JL; Armstrong S; Biddinger PW; Miller MA; Balakrishnan K; Wilson KM; Saavedra HI; Stambrook PJ
    Arch Otolaryngol Head Neck Surg; 1998 Oct; 124(10):1097-104. PubMed ID: 9776187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-Time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for the measurement of prostate-specific antigen mRNA in the peripheral blood of patients with prostate carcinoma using the taqman detection system.
    Gelmini S; Tricarico C; Vona G; Livi L; Melina AD; Serni S; Cellai E; Magrini S; Villari D; Carini M; Serio M; Forti G; Pazzagli M; Orlando C
    Clin Chem Lab Med; 2001 May; 39(5):385-91. PubMed ID: 11434386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results.
    Gelet A; Chapelon JY; Bouvier R; Pangaud C; Lasne Y
    J Urol; 1999 Jan; 161(1):156-62. PubMed ID: 10037389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of human bone marrow mesenchymal stromal cells on cytokine production by peripheral blood naive, memory, and effector T cells.
    Laranjeira P; Pedrosa M; Pedreiro S; Gomes J; Martinho A; Antunes B; Ribeiro T; Santos F; Trindade H; Paiva A
    Stem Cell Res Ther; 2015 Jan; 6(1):3. PubMed ID: 25559824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.
    Herman JR; Adler HL; Aguilar-Cordova E; Rojas-Martinez A; Woo S; Timme TL; Wheeler TM; Thompson TC; Scardino PT
    Hum Gene Ther; 1999 May; 10(7):1239-49. PubMed ID: 10340555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
    Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
    Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G
    Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.